Diabetes Mellitus
Conditions
Keywords
Hyperlipidemia, Proteinuria, Diabetes Mellitus
Brief summary
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and hypercholesterolaemia.
Interventions
DRUGRosuvastatin
10 mg oral dose administered once daily for 52 weeks
DRUGAtorvastatin
40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* hyperlipidemia * urinary protein * diabetes
Exclusion criteria
* previous rosuvastatin treatment \< 6 months prior to Visit 1 * statin intolerance * severe hypertension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. | Assessed at Week 52, Last observation carried forward (LOCF) | Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Albumin/Creatinine Ratio at Week 26 | Assessed at Week 26 | Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio. |
| Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | Assessed at Week 52 LOCF | Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio. |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | Assessed at Baseline and Week 26 | — |
| Change From Baseline in eGFR at Week 52 [LOCF] | Assessed at Baseline and Week 52 [LOCF] | — |
| Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes | 52 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF). |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC | Assessed at 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C] | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C | 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C] | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C | 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C] | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C | 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG] | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG | 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1] | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1 | 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB] | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB | 52 Weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 |
| Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | 26 weeks | Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 26 weeks | Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and TC | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and TG | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Urinary Protein/Creatinine Ratio at Week 26. | Assessed at Week 26 | Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
| Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | 26 weeks | Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. |
Countries
Argentina, Brazil, Bulgaria, Canada, Denmark, France, Hungary, Italy, Mexico, Romania, United States
Participant flow
Recruitment details
353 patients entered the study with Type 1 or 2 diabetes and were receiving current treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs). The study was conducted at 147 centers in 11 countries.
Pre-assignment details
Patients requiring an adjustment of the ACE inhibitor and/or ARBs after Visit 1 were excluded. All 353 patients were randomized and 276 patients completed the study.
Participants by arm
| Arm | Count |
|---|---|
| Rosuvastatin 10mg | 118 |
| Rosuvastatin 40mg | 124 |
| Atorvastatin 80mg | 111 |
| Total | 353 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 14 | 10 | 7 |
| Overall Study | Incorrect enrollment | 3 | 3 | 4 |
| Overall Study | Lost to Follow-up | 3 | 1 | 1 |
| Overall Study | Nephrologist introduced ACE | 0 | 1 | 0 |
| Overall Study | Other | 0 | 0 | 1 |
| Overall Study | Pregnancy | 0 | 0 | 2 |
| Overall Study | Protocol Violation | 1 | 2 | 3 |
| Overall Study | Relocated to another state | 1 | 0 | 0 |
| Overall Study | Stopped drug before end of study visit | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 5 | 11 |
Baseline characteristics
| Characteristic | Total | Atorvastatin 80mg | Rosuvastatin 10mg | Rosuvastatin 40mg |
|---|---|---|---|---|
| Age, Customized 18-49 years | 80 Participants | 25 Participants | 22 Participants | 33 Participants |
| Age, Customized 50-64 years | 175 Participants | 57 Participants | 59 Participants | 59 Participants |
| Age, Customized >=65 years | 98 Participants | 29 Participants | 37 Participants | 32 Participants |
| Estimated glomerular filtration rate [eGFR] | 71.210 mL/min STANDARD_DEVIATION 24.9455 | 72.149 mL/min STANDARD_DEVIATION 24.8721 | 68.759 mL/min STANDARD_DEVIATION 24.108 | 72.644 mL/min STANDARD_DEVIATION 25.8018 |
| Sex: Female, Male Female | 108 Participants | 33 Participants | 43 Participants | 32 Participants |
| Sex: Female, Male Male | 245 Participants | 78 Participants | 75 Participants | 92 Participants |
| Urine albumin/creatinine ratio | 1085.435 mg/g STANDARD_DEVIATION 743.536 | 1143.198 mg/g STANDARD_DEVIATION 779.5282 | 1036.478 mg/g STANDARD_DEVIATION 730.6185 | 1079.802 mg/g STANDARD_DEVIATION 725.7039 |
| Urine protein/creatinine ratio | 1467.843 mg/g STANDARD_DEVIATION 952.038 | 1517.858 mg/g STANDARD_DEVIATION 969.702 | 1392.26 mg/g STANDARD_DEVIATION 888.3215 | 1493.574 mg/g STANDARD_DEVIATION 996.0972 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 15 / 116 | 25 / 123 | 12 / 110 |
| serious Total, serious adverse events | 18 / 116 | 20 / 123 | 21 / 110 |
Outcome results
Primary
Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at Week 52, Last observation carried forward (LOCF)
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10mg | Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. | 1.016 mg/g |
| Rosuvastatin 40mg | Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. | 0.955 mg/g |
| Atorvastatin 80mg | Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. | 0.874 mg/g |
Secondary
Change From Baseline in eGFR at Week 52 [LOCF]
Time frame: Assessed at Baseline and Week 52 [LOCF]
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin 10mg | Change From Baseline in eGFR at Week 52 [LOCF] | -3.70 mL/min | Standard Deviation 14.551 |
| Rosuvastatin 40mg | Change From Baseline in eGFR at Week 52 [LOCF] | -7.29 mL/min | Standard Deviation 20.04 |
| Atorvastatin 80mg | Change From Baseline in eGFR at Week 52 [LOCF] | -1.61 mL/min | Standard Deviation 12.769 |
Secondary
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Time frame: Assessed at Baseline and Week 26
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin 10mg | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | -2.73 mL/min | Standard Deviation 12.644 |
| Rosuvastatin 40mg | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | -5.46 mL/min | Standard Deviation 14.079 |
| Atorvastatin 80mg | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | -1.78 mL/min | Standard Deviation 10.997 |
Secondary
Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes | -0.03507 Correlation coefficient |
| Rosuvastatin 40mg | Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes | 0.14258 Correlation coefficient |
| Atorvastatin 80mg | Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes | 0.01600 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.17909 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.08090 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.12787 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.08146 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.05333 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1 | 0.05845 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | -0.15146 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | 0.04886 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | -0.12168 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | -0.01427 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | 0.08821 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB | 0.00737 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | -0.26146 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | 0.05248 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | -0.22109 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | -0.04088 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | 0.06598 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio | -0.01652 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.11373 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.01123 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.07576 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.14457 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | -0.15546 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C | 0.08841 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | -0.11072 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | -0.12835 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | -0.11378 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | 0.03010 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | -0.00944 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C | 0.02609 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | -0.19850 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | -0.06481 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | -0.17579 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | -0.01040 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | 0.00241 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio | 0.00189 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.01709 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.05610 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.02569 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.17729 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.19501 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C | -0.17911 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.26802 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.11804 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.24204 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.06356 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.04402 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio | -0.05499 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC | 0.01586 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC | -0.03124 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC | 0.00101 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC | -0.13489 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC | -0.18105 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC | -0.14690 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.26268 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.08593 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.23226 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.05426 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.01643 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio | -0.04256 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.10533 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.00604 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.09437 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.24494 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.07059 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: eGFR and TG | -0.15586 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.16085 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.15933 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.17306 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.14207 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.11171 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1 | 0.13429 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 0.10997 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 0.30537 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 0.15652 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | -0.00569 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 0.20008 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB | 0.04833 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | -0.05906 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.13706 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | -0.01775 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.04760 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.25636 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.07766 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.14758 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.26805 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.17550 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.08593 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.00032 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C | 0.06930 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 0.10037 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 0.21205 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 0.12270 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | -0.05514 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 0.19842 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C | 0.00038 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.03476 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.10902 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.04508 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.08211 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.16654 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.03001 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | -0.06694 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | 0.17296 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | -0.01144 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | 0.09189 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | 0.33769 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C | 0.14988 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.08468 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.12805 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.04102 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.01528 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.21198 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.05251 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.13220 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.35715 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.18971 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.00642 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.14331 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC | 0.04311 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | 0.01798 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | 0.20127 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | 0.05369 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | -0.04785 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | 0.11256 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio | -0.01362 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | -0.02947 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | 0.27198 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | 0.08787 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | -0.07271 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | 0.08654 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG | -0.02876 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1 | 0.16587 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1 | 0.18469 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1 | 0.18832 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB | 0.05397 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB | 0.29486 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB | 0.11079 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | -0.07846 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.13910 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | -0.02825 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.00600 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.22710 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio | 0.03684 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1] | 0.15859 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1] | 0.13133 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1] | 0.15516 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB] | -0.02276 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB] | 0.21405 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB] | 0.04578 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C | 0.16111 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C | 0.26194 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C | 0.18918 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C] | 0.15614 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C] | 0.06987 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C] | 0.14226 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C | 0.04510 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C | 0.16280 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C | 0.06739 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.02775 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.06535 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.01569 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.13689 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | 0.12931 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio | -0.08108 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C] | -0.08588 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C] | 0.18570 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C] | -0.02491 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C | 0.02594 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C | 0.24018 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C | 0.07381 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.06085 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.12507 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.02841 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.16755 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | 0.08891 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio | -0.11221 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C] | -0.12068 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C] | 0.15929 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C] | -0.05186 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | -0.05945 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | 0.12132 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | -0.02666 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | -0.13572 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | 0.07339 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio | -0.08855 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG | -0.05251 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG | 0.11755 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG | 0.01345 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG] | -0.14569 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG] | 0.04948 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG] | -0.08471 Correlation coefficient |
Secondary
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52
Time frame: Assessed at 52 Weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin 10mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC | 0.07019 Correlation coefficient |
| Rosuvastatin 40mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC | 0.26855 Correlation coefficient |
| Atorvastatin 80mg | Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC | 0.12013 Correlation coefficient |
Secondary
Urinary Albumin/Creatinine Ratio at Week 26
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at Week 26
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10mg | Urinary Albumin/Creatinine Ratio at Week 26 | 0.927 mg/g |
| Rosuvastatin 40mg | Urinary Albumin/Creatinine Ratio at Week 26 | 0.913 mg/g |
| Atorvastatin 80mg | Urinary Albumin/Creatinine Ratio at Week 26 | 0.831 mg/g |
Secondary
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at Week 52 LOCF
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10mg | Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 1.016 mg/g |
| Rosuvastatin 40mg | Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 0.836 mg/g |
| Atorvastatin 80mg | Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 0.823 mg/g |
Secondary
Urinary Protein/Creatinine Ratio at Week 26.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at Week 26
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Rosuvastatin 10mg | Urinary Protein/Creatinine Ratio at Week 26. | 1.007 mg/g |
| Rosuvastatin 40mg | Urinary Protein/Creatinine Ratio at Week 26. | 0.994 mg/g |
| Atorvastatin 80mg | Urinary Protein/Creatinine Ratio at Week 26. | 0.876 mg/g |